Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023.
- Second-quarter revenue came in at $1.61 billion, which is up 1% year-over-year
- Earnings per share increased to $0.95 in the June quarter from $0.92 last year
- Adjusted earnings were $1.31 per share in Q2, compared to $1.25 per share in the second quarter of 2022
- The company reported second-quarter adjusted EBITDA of $530 million, which is up 4% annually
- The management expects full-year 2023 revenue to be in the range of $6.25 billion to $6.45 billion
- Adjusted EBITDA margin for 2023 is currently expected to be between 31.5% and 33.0%
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
